Centogene has received a notification from Nasdaq indicating that its common stock cannot continue to be listed due to non-compliance with Nasdaq Listing Rule 5450(b)(2)(C), failing to maintain a minimum market value of USD 15 million for publicly held shares. The company held a hearing with Nasdaq on April 30, 2024, to present a plan to regain compliance related to closing a sale transaction by August 26, 2024, which the company has been unable to complete.
Trading of Centogene's common stock on Nasdaq will be suspended starting from August 8, 2024. The company may request a review of Nasdaq's decision within 15 days, although it has decided not to. Trading is expected to shift to the Over The Counter (OTC) Markets Group platform under the symbol "CNTGF."
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.